Clinical Trials Directory

Trials / Completed

CompletedNCT05747352

Safety of Closed-loop Hybrid Insulin Administration During Ramadan Fasting in People Living With Type 1 Diabetes

Evaluation of the Glycemic Profile During the Ramadan Fasting in People With Type 1 Diabetes Treated With Closed-loop Hybrid Insulin System

Status
Completed
Phase
Study type
Observational
Enrollment
23 (actual)
Sponsor
Centre Hospitalier Sud Francilien · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Fasting in Ramadan is not recommended for people with type 1 diabetes. The main risk associated with fasting is dysglycemia (hypoglycemia, hyperglycemia, diabetic ketosis) and dehydration. Nevertheless, whether or not to practice Ramadan remains a personal choice and many people living with diabetes choose to perform this fast with or without their physician's approval. The purpose of this prospective observational study is to evaluate the safety and efficacy of an closed-loop hybrid insulin system on glycemic parameters and the level of hypoglycemia in patients with type 1 diabetes who wished to fast during Ramadan.

Detailed description

Primary objective: to evaluate the efficacy of an closed-loop hybrid insulin system on continuous glucose monitoring (CGM) glycemic parameters during the Ramadan fasting period Primary endpoint : to compare the time spent in the 3.9-10.0 mmol/l glucose target (TIR) from 30 days prior to the Ramadan fasting period to 30 days during the fasting period

Conditions

Interventions

TypeNameDescription
OTHERclosed-loop hybrid insulin administrationobservational non-interventional study

Timeline

Start date
2023-06-05
Primary completion
2023-09-13
Completion
2023-09-13
First posted
2023-02-28
Last updated
2023-11-07

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05747352. Inclusion in this directory is not an endorsement.